Arix Bioscience Plc’s (LON:ARIX) portfolio company, Autolus Therapeutics PLC (NASDAQ:AUTL), has dosed the first patient in a Phase 1/2 clinical trial of its AUTO4 therapy for relapsed or refractory TRBC1-positive peripheral T cell lymphoma (PTCL).
PTCL is a form of cancer that arises in areas of the body such as lymph nodes, spleen, the gastrointestinal tract, and skin when T-cells, white blood cells that fight infection, become abnormal.
The first phase of the trial is expected to enrol around 25 patients and evaluate up to three dose levels of the AUTO4 therapy, beginning with a low dose of 25mln AUTO4 cells in cohorts of three to six patients.
If no toxicities are observed, the doses will then escalate to 75mln and 225mln until a recommended dose has been identified, after which up to 30 patients will be enrolled in Phase 2.
Arix also said that data from Autolus’ preclinical programme for AUTO5, a sister to AUTO4 targeting TRBC2-positive lymphoma, was presented at the annual meeting of the American Society of Hematology (ASH) on 2 December.
In a separate announcement, the company added that clinical data from Phase 1/2 trials of Autolus’ AUTO3 treatment had also been presented at the ASH conference.
AUTO3 is a treatment targeting paediatric acute lymphoblastic leukemia, the single most common form of cancer in children, and diffuse large B cell lymphoma, a cancer that affects B-cells which produce antibodies.
The news follows early-stage clinical trial successes from another of the firm’s company’s, Australian firm Pharmaxis (ASX:PXS) in November.
A two-part phase I clinical study revealed Pharmaxis’ drug was safe and there were no adverse reactions.